Market Cap : 182.26 M | Enterprise Value : 119.89 M | PE Ratio : At Loss | PB Ratio : 2.91 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. VistaGen Therapeutics's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-66.75 Mil. VistaGen Therapeutics's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $72.35 Mil. Therefore, VistaGen Therapeutics's annualized ROE % for the quarter that ended in Mar. 2022 was -92.27%.
The historical rank and industry rank for VistaGen Therapeutics's ROE % or its related term are showing as below:
During the past 13 years, VistaGen Therapeutics's highest ROE % was -60.44%. The lowest was -3274.59%. And the median was -367.78%.
VTGN's ROE % is ranked worse thanThe historical data trend for VistaGen Therapeutics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VistaGen Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's ROE % distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's ROE % falls into.
VistaGen Therapeutics's annualized ROE % for the fiscal year that ended in Mar. 2022 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (A: Mar. 2022 ) | / | ( (Total Stockholders Equity (A: Mar. 2021 ) | + | Total Stockholders Equity (A: Mar. 2022 )) | / count ) |
= | -48.708 | / | ( (91.979 | + | 64.715) | / 2 ) | |
= | -48.708 | / | 78.347 | ||||
= | -62.17 % |
VistaGen Therapeutics's annualized ROE % for the quarter that ended in Mar. 2022 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (Q: Mar. 2022 ) | / | ( (Total Stockholders Equity (Q: Dec. 2021 ) | + | Total Stockholders Equity (Q: Mar. 2022 )) | / count ) |
= | -66.752 | / | ( (79.978 | + | 64.715) | / 2 ) | |
= | -66.752 | / | 72.3465 | ||||
= | -92.27 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE %** | (Q: Mar. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -66.752 | / | 72.3465 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-66.752 / 0.156) | * | (0.156 / 82.5895) | * | (82.5895 / 72.3465) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -42789.74 % | * | 0.0019 | * | 1.1416 |
= | ROA % | * | Equity Multiplier | ||
= | -81.3 % | * | 1.1416 | ||
= | -92.27 % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE %** | (Q: Mar. 2022 ) | ||||||||
= | Net Income | / | Total Stockholders Equity | ||||||
= | -66.752 | / | 72.3465 | ||||||
= | (Net Income /Pre-Tax Income) | * | (Pre-Tax Income/Operating Income) | * | (Operating Income/Revenue) | * | (Revenue/Total Assets) | * | (Total Assets/Total Stockholders Equity) |
= | (-66.752 / -66.752) | * | (-66.752 / -66.772) | * | (-66.772 / 0.156) | * | (0.156 / 82.5895) | * | (82.5895 / 72.3465) |
= | Tax Burden | * | Interest Burden | * | Operating Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 1 | * | 0.9997 | * | -42802.56 % | * | 0.0019 | * | 1.1416 |
= | -92.27 % |
Note: The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
Net income attributable to common stockholders is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of VistaGen Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Zacks 2021-06-16
By tipranks.com 2022-03-03
By Zacks 2021-02-11
By Seekingalpha 2021-11-10
By Zacks 2021-11-10
By Seekingalpha 2021-01-24
By Zacks 2021-10-20
By Fool 2021-06-30
By Zacks 2022-02-10
By Seekingalpha 2021-06-29
By Seekingalpha 2022-02-10
By Zacks 2021-08-12
By tipranks.com 2022-02-13